Spinogenix has filed a notice of an exempt offering of securities to raise $5,199,985.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Spinogenix is raising $5,199,985.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Stella Sarraf played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Spinogenix
Who we are In most neurodegenerative diseases we lose connections – synapses between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. Mission Our mission is to create transformative therapeutics for diseases involving synaptic loss and dysfunction. Our approach is focused on regenerating synapses to reverse declines in cognitive and motor function. This approach is unique among the many therapeutics that are being developed for neurodegenerative conditions, which mostly aim to slow the degenerative process. We envision the use of SPGs as a monotherapy or in combination with other therapeutics that target disease-specific degenerative processes. Our Science In contrast to much research focused on alleviating the symptoms of neurodegenerative disease, we seek to develop therapies that impact the underlying disease and fundamentally change treatment paradigms by restoring neuronal connections regardless of the underlying cause of synapse loss. Spinogenix has discovered compounds (SPGs) that restore lost synapses. We have demonstrated the effectiveness of these spinogenic molecules in cells and in multiple animal models of neurodegeneration. SPGs have a novel molecular target and their mechanism of action is well understood and unique. This mechanism would be operative in all diseases where synapse loss occurs, irrespective of the pathological basis of synapse loss.
To learn more about Spinogenix, visit http://www.spinogenix.com/
Contact:
Stella Sarraf, President and Chief Executive Officer
858-263-3252
https://www.linkedin.com/in/stellasarraf/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.